Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline timing for follicular resolution
NCT04096027Phase 4Completed
- Sponsor
- Fertility Center of Las Vegas
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cabergoline in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Fertility Center of Las Vegas. Primary endpoints: Discomfort level and Mature oocyte rate per follicular puncture. Started Sep 2019; status: completed.
02
Drugs
cabergoline
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT04096027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096027.